Investigating the aetiopathogenic role of autoantibodies against the M1 muscarinic acetylcholine receptor in patients with first episode of schizophrenia

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1101255

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Previously we have found that a proportion of patients with schizophrenia have elevated levels of antibodies that target one of the neurotransmitter receptors, the M1 muscarinic acetylcholine receptor, and that those patients who have the highest levels of antibodies tend to have more severe manifestations of some of the symptoms of schizophrenia. In this project, we will try to confirm this relationship, and also investigate further how this antibodies might be able to worsen specific symptoms.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $830,986.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Autoimmunity

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

autoantibodies | disease mechanisms | human leukocyte antigen (HLA) typing | muscarinic receptors | schizophrenia

Related Links